New insider activity at Precigen ( (PGEN) ) has taken place on August 29, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Nancy Agee has made a significant investment in Precigen by purchasing 26,005 shares of the company’s stock, valued at $98,544.
Recent Updates on PGEN stock
Precigen’s stock has experienced significant developments recently, primarily driven by the FDA’s approval of their product PAPZIMEOS for the treatment of recurrent respiratory papillomatosis (RRP). This approval has led to a notable increase in the company’s stock price, with a reported surge of over 60%. Analysts have responded positively, with Citizens JMP raising their price target due to the higher than expected wholesale acquisition cost of PAPZIMEOS, set at $460k per patient. H.C. Wainwright also increased their price target, highlighting the FDA’s early approval as a reflection of the unmet need in RRP and projecting substantial future sales. These developments have positioned Precigen favorably in the market, despite ongoing concerns about financial performance and valuation metrics.
Spark’s Take on PGEN Stock
According to Spark, TipRanks’ AI Analyst, PGEN is a Neutral.
Precigen’s overall stock score is driven by strong technical momentum and positive corporate events, offset by weak financial performance and valuation concerns. The FDA approval and supply agreement are significant positives, while financial instability remains a major risk.
To see Spark’s full report on PGEN stock, click here.
More about Precigen
YTD Price Performance: 321.30%
Average Trading Volume: 7,026,771
Technical Sentiment Signal: Buy
Current Market Cap: $1.36B